Trending News Today: Mylan EpiPen Shortages Seen in Canada, UK

Mylan’s emergency allergy antidote, EpiPen, is in short supply in Canada and Britain but remains available in the United States, Reuters reported. According to the article, Pfizer Canada announced that it was experiencing supply constraints for EpiPens due to delays at the manufacturing facility, as well as problems in sourcing a component for the device from an outside supplier. Federal health officials said that there are currently no alternatives on the market in Canada, according to Reuters.
 
President Donald Trump is scheduled to give a speech on lowering prescription drug prices on April 26, The Hill reported. However, the White House has indicated that no new policy proposals will be unveiled at the speech other than a request for information on various drug pricing ideas, according to the article. Both Trump and Health and Human Services Secretary Alex Azar said last month that the administration would soon be rolling out new drug pricing proposals, the article noted. 
 
An online Canadian pharmacy was fined $34 million Friday for importing counterfeit cancer drugs and other unapproved pharmaceuticals into the United States, ABC News reported. According to the article, US prosecutors say Canada Drugs’ business model is based entirely on illegally importing unapproved and misbranded drugs from all over the world, and that the company has made at least $78 million through illegal imports. Two of these imports included counterfeit versions of the cancer drugs Avastin and Altuzan, ABC News reported. 


Stay up to date on the latest news in specialty pharmacy by getting Specialty Pharmacy Times in your mailbox or inbox for free!

Click here to sign up for free for the bi-monthly Specialty Pharmacy Times print journal delivered to your address.

Click here to sign up for our email newsletters delivered every Monday, Wednesday, and Friday, in addition to breaking news alerts.

Click here to follow us on Facebook. 

Click here to follow us on Twitter. 

Click here to join our LinkedIn group. 


Most Popular

Related Articles

Study examines whether markers of biological aging due to cancer treatment are related to cognitive function in survivors of breast cancer.
Thom Cohn, Chief Strategy Officer, Asembia, discusses special considerations for the launch of a personalized drug.
Atezolizumab (Tecentriq) approved by FDA in combination with bevacizumab (Avastin), carboplatin, and paclitaxel for the first-line treatment of metastatic nonsquamous non-small cell lung cancer.
Company Profile >
Contributors >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Advertise
Careers
Contact Us
Terms & Conditions
Privacy
MJH Associates >
Pharmacy Times
OTCGuide
American Journal of Managed Care
Cure
MD Magazine
ONCLive
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2018
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.
 

$vacMongoViewPlus$